Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Therapeutic prime/pull vaccination of HSV-2-infected guinea pigs with the ribonucleotide reductase 2 (RR2) protein and CXCL11 chemokine boosts antiviral local tissue-resident and effector memory CD4 + and CD8 + T cells and protects against recurrent genital herpes

Journal of Virology(2024)10.1128/jvi.01596-23Source: DataRank Database

Therapeutic prime/pull vaccination of HSV-2-infected guinea pigs with the ribonucleotide reductase 2 (RR2) protein and CXCL11 chemokine boosts antiviral local tissue-resident and effector memory CD4 + and CD8 + T cells and protects against recurrent genital herpes is a research paper published in Journal of Virology (2024). On theSindex it has a DataRank of 0.534. It has been cited 19 times, with 12 citing works in its 1-hop citation network.

N/A

0.534DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access19 citations · 12 citing works in its network

Download PDF

Cite:

Data availability

Repositories this paper deposited data in (declared in PubMed).

GEOGSE261599

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (18 grants)Impact (FWCI 5.39)OA: greenTopics (37)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 84%Citation Network 16%

Base Score Contribution

0.449

From this paper's citation signal

Citation Network Contribution

0.0851

From 6 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 12 citers.

An intranasally- and intramuscularly-deliverable nanostructured lipid carrier-replicon RNA vaccine drives protective systemic and mucosal immunity
Journal of Controlled Release20257 citations64 referencesContributes 0.032
Role of inflammasomes in cancer immunity: mechanisms and therapeutic potential
Journal of Experimental & Clinical Cancer Research202530 citations148 referencesContributes 0.023
Complete cross strain protection against congenital cytomegalovirus infection requires a vaccine encoding key antibody (gB) and T-cell (immediate early 1 protein) viral antigens
Frontiers in Immunology20253 citations92 referencesContributes 0.015
Herpes Simplex Virus Type 2 Screening in Persons with and Without HIV: Evidence, Challenges, and Future Directions
Current HIV/AIDS Reports20264 citations135 referencesContributes 0.012
Development of an Intranasally- and Intramuscularly-Administrable Replicon Vaccine Efficacious Against H5N1 Influenza Virus
bioRxiv (Cold Spring Harbor Laboratory)20251 citations59 referencesContributes 0.012

Authors (13)

Swayam Prakash ORCID,Nisha R. Dhanushkodi ORCID,Mahmoud Singer ORCID,Latifa Zayou ORCID,Amin Mohammed Shaik ORCID

Live enrichment

PubMed:38587378 PMC:PMC11092353 OpenAlex:https://openalex.org/W4394568900

HHS | NIH | National Eye Institute

Grant: EY026103, EY019896, EY024618

HHS | NIH | National Institute of Allergy and Infectious Diseases

Grant: AI158060, AI150091, AI143348, AI147499, AI143326, AI138764, AI124911, AI110902

NIAID NIH HHS

Grant: R01 AI143348

NIAID NIH HHS

Grant: R01 AI158060

NIAID NIH HHS

Grant: R21 AI143326

NEI NIH HHS

Grant: R01 EY019896

NEI NIH HHS

Grant: R01 EY024618

NIAID NIH HHS

Grant: R01 AI150091

NEI NIH HHS

Grant: R01 EY026103

NIAID NIH HHS

Grant: R21 AI110902

NIAID NIH HHS

Grant: R21 AI147499

NIAID NIH HHS

Grant: R41 AI138764

NIAID NIH HHS

Grant: R43 AI124911

National Institutes of Health

Grant: 5R01EY024618-03

Blockade of T-cell Co-Inhibitory Pathways & Immunotherapy to Prevent Ocular Herpe

National Institutes of Health

Grant: 1R43AI124911-01

A NOVEL IMMUNO-PROTEOMIC APPROACH TO A GENITAL HERPES VACCINE

National Institutes of Health

Grant: 1R41AI138764-01

A NOVEL SELF-ASSEMBLING PROTEIN NANOPARTICLES-BASED GENITAL HERPES VACCINE

National Institutes of Health

Grant: 5R21AI143326-02

Impact of Immune Checkpoints Blockade on HSV-1 Neuro-Pathogenesis

National Institutes of Health

Grant: 5R21AI110902-02

LAT-HVEM Interactions Effect HSV-1 Latency/Reactivation

FWCI

5.39

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

greenLicense: https://doi.org/10.1128/ASMCopyrightv2

repositoryhttps://escholarship.org/content/qt6pc9s9sx/qt6pc9s9sx.pdf

publisherhttps://journals.asm.org/doi/pdf/10.1128/jvi.01596-23

repositoryhttps://escholarship.org/uc/item/6pc9s9sx

journalhttps://doi.org/10.1128/jvi.01596-23

Fields of Study

Herpesvirus Infections and TreatmentsImmune Response and InflammationCytomegalovirus and herpesvirus research0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

Memory T CellsAnimalsDisease Models, AnimalFemaleGanglia, SpinalGuinea PigsHerpes GenitalisRibonucleotide ReductasesVaccinationVaginaCD4-Positive T-LymphocytesHerpesvirus 2, HumanCD8-Positive T-LymphocytesChemokine CXCL11

Keywords

CXCL9BiologyVirologyVirusCD8ChemokineImmunologyHerpes simplex virusCXCL11CXCL10Immune systemT cellsChemokinesTherapeuticGenital HerpesVaginal MucosaPrime/pull Vaccine

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being